You are here
The cutting-edge innate immunity research at the Center for Innate Immunity and Immune Disease (CIIID) is advancing therapeutics and vaccine technology for immune enhancement and protection against infection and immune diseases.
CIIID researchers are using cutting approaches to identify cellular targets for therapeutic strategies aimed at modifying the immune response through innate immune regulation. Our researchers are developing both biologics and small molecules that target and regulate innate immune intracellular pathways and immune cell activation programs to suppress microbial infection, including infection by contemporary and emerging viral pathogens, and are building improved immune adjuvants to enhance vaccine protection against a variety of pathogens. CIIID researchers are also targeting innate immune processes to dampen the immune response for the control of autoimmuity and inflammation that underlie immune disease such as systematic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS).
CIIID research is advancing vaccine technology by building new vaccines that directly target innate and adaptive immune-inducing process of the body using safe, non-infectious vaccine platforms for prophylactic and therapeutic vaccine actions to protect against virus infection and to treat chronic infection conditions.
CIIID investigators are actively developing new therapeutics and vaccines against a broad range of diseases and infectious agents including SLE, RA, MS, and infection caused by parasites such as Malaria and other protozoa, bacteria including Mycobacterium tuberculosis and Salmonella, and viruses including ebola virus, West Nile Virus, respiratory syncytial virus, dengue virus, nipah virus, Lassa fever virus, influenza A virus, HIV, hepatitis C virus, and hepatitis B virus.